Novo Nordisk's Amycretin Delivers Up to 14.6% Weight Loss in Phase 2 Diabetes Trial

What Happened

Fresh international attention is falling on the strongest mid-stage diabetes dataset in Novo Nordisk's pipeline. Amycretin, also known as zenagamtide, produced average weight loss of up to 14.6% alongside strong blood-sugar reductions in a phase 2 trial of adults with type 2 diabetes — data presented at both major 2026 diabetes congresses and now re-circulating internationally.

Amycretin is the first candidate of its kind: a single peptide molecule activating both the GLP-1 receptor and the amylin receptor — the same two-receptor biology behind Novo's separate CagriSema program, but packed into one molecule rather than two co-formulated drugs.

The 36-week dose-finding trial enrolled 448 adults with type 2 diabetes inadequately controlled on metformin, testing six weekly subcutaneous doses against placebo:

• Body weight: from a mean baseline of roughly 219 lbs (99.2 kg), the highest tested dose produced an average weight reduction of 14.6% versus 2.1% with placebo. Effects scaled across all six doses, and no weight-loss plateau was visible at trial end — even though top-dose participants spent only four to eight weeks at full maintenance strength.

Blood sugar: average HbA1c fell by up to 1.71 points from a baseline of 7.8%. Up to 89.1% of participants reached HbA1c below 7%, 76.2% reached 6.5% or lower, and up to 91.5% of monitoring time fell inside the 70-180 mg/dL target range.

Safety: generally well tolerated, with mostly mild-to-moderate gastrointestinal effects typical of incretin and amylin-based therapies.

A once-daily oral formulation produced weight loss of up to 10.1% and HbA1c reductions of up to 1.5 points — an early look at the injection-free version Novo wants to bring to market.

Who Is Affected

• Adults with type 2 diabetes, who often struggle with weight alongside poor glucose control; a dual-effect single molecule could intensify both benefits.
• People with obesity, as phase 3 weight-management trials of both the injectable and oral forms are underway.
• Competitors building dual and triple agonists, now facing a rival pairing amylin with GLP-1 instead of GIP.
• Research peptide buyers, as amycretin-like products already appear in gray-market catalogs with no purity guarantees.

Timeline

• 25 November 2025: Novo Nordisk announces positive phase 2 topline results in type 2 diabetes.
• June 2026: Full dose-response data presented at the American Diabetes Association scientific sessions.
• 30 September 2026: The dataset features in an oral presentation at EASD 2026, Europe's leading diabetes congress.
• Second half of 2026: Phase 3 development in type 2 diabetes scheduled to begin, alongside the ongoing obesity program.

What This Means for Researchers

• Amylin biology is validated in a single molecule. The results confirm what CagriSema suggested: amylin agonism adds meaningful weight loss on top of GLP-1 activity.
• The no-plateau signal matters. Weight was still declining at week 36 despite minimal time at full maintenance dose, so phase 3 ceilings may sit higher.
• Watch for head-to-head trials against dual GIP/GLP-1 products.

How to Verify Your Peptides

Amycretin is investigational — no approved version exists anywhere — so any product sold under that name today is an unapproved research chemical of unknown composition. If your lab encounters one:

• Start with our overview of how peptide testing works.
• Confirm identity with LC-MS versus HPLC methods.
• The semaglutide testing and purity workflow transfers directly to incretin-family peptides like amycretin.

Safe Alternatives

• The semaglutide peptide profile covers the approved GLP-1 class member with established testing norms.
• For sourcing, use the vetted vendor directory, not unverifiable gray-market sellers.

Sources

Industry reports and company clinical announcements, 2025-2026.